SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials

@article{Zelniker2019SGLT2IF,
  title={SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials},
  author={Thomas A. Zelniker and Stephen D. Wiviott and Itamar Raz and Kyungah Im and Erica L. Goodrich and Marc P. Bonaca and Ofri Mosenzon and Eri Toda Kato and Avivit Cahn and Remo H M Furtado and Deepak L. Bhatt and Lawrence A Leiter and Darren K Mcguire and John P H Wilding and Marc S. Sabatine},
  journal={The Lancet},
  year={2019},
  volume={393},
  pages={31-39}
}

Figures from this paper

Effect of SGLT-2 Inhibitors on Cardiovascular Outcomes Among Patients With Heart Failure and Type 2 Diabetes Mellitus: A Systemic Review and Meta-Analysis of Randomized Controlled Trials
TLDR
SGLT-2i significantly reduced the risk of HHF and ACM in a broad range of HF patients concomitant with T2DM and was associated with a reduction in serious adverse events.
Effects of sodium‐glucose cotransporter type 2 inhibitors on cardiovascular, renal, and safety outcomes in patients with cardiovascular disease: a meta‐analysis of randomized controlled trials
TLDR
A systematic review and meta-analysis revealed that SGLT-2i treatment significantly reduced all-cause mortality, cardiovascular mortality, and hospitalisation for heart failure (HHF) in patients with cardiovascular disease and induced a lower incidence of renal damage and myocardial infarction than the placebo group.
Effects of SGLT2 inhibitors on cardiovascular and renal outcomes in type 2 diabetes
TLDR
Trial sequential analyses for MI and stroke showed that cumulative Z curve did not cross trial sequential monitoring boundary and required information size, whereas those for the other 6 endpoints showed that Cumulative Z curve crossed trial sequential Monitoring boundary and/or required information sizes.
SGLT2 inhibitors in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials balancing their risks and benefits
TLDR
In a population of individuals with type 2 diabetes and a high CVD risk, the cardiovascular and renal benefits of SGLT2i remain substantial despite the risk of DKA and even the hypothetical risk of amputation.
Effects of SGLT2 inhibitors on cardiovascular death and all-cause death in patients with type 2 diabetes and chronic kidney disease: an updated meta-analysis including the SCORED trial
TLDR
It is suggested that SGLT2 inhibitors versus placebo significantly lower death, heart failure, renal failure, and MI events in patients with T2D and CKD and head-to-head trials are needed to examine the possible differences in the effects of various gliflozins on MACE and stroke.
Impact of SGLT2 inhibitors on major clinical events and safety outcomes in heart failure patients: a meta-analysis of randomized clinical trials
TLDR
In patients with HF, regardless of LVEF phenotype, all SGLT2i had an excellent safety profile and significantly reduced the risk of all-cause mortality, CV mortality, HF hospitalizations and CV deaths/HF hospitalizations compared to placebo.
...
...

References

SHOWING 1-10 OF 47 REFERENCES
Effects of SGLT-2 inhibitors on mortality and cardiovascular events: a comprehensive meta-analysis of randomized controlled trials
TLDR
Available data suggest that the beneficial action observed with empagliflozin on all-cause and cardiovascular mortality in EMPAREG OUTCOME study is a class effect.
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
TLDR
The cardiovascular safety profile of dapagliflozin, a selective inhibitor of sodium–glucose cotransporter 2 that promotes glucosuria in patients with type 2 diabetes, is undefined.
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
TLDR
In patients with type 2 diabetes who had or were at risk for atherosclerotic cardiovascular disease, treatment with dapagliflozin did not result in a higher or lower rate of MACE than placebo but did result in anLower rate of cardiovascular death or hospitalization for heart failure, a finding that reflects a lower rates of hospitalizationFor heart failure.
Canagliflozin for Primary and Secondary Prevention of Cardiovascular Events
TLDR
Canagliflozin reduced cardiovascular and renal outcomes with no statistical evidence of heterogeneity of the treatment effect across the primary and secondary prevention groups.
Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes.
TLDR
In patients with type 2 diabetes at high cardiovascular risk, empagliflozin was associated with slower progression of kidney disease and lower rates of clinically relevant renal events than was placebo when added to standard care.
Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease
TLDR
Empagliflozin improved clinical outcomes and reduced mortality in vulnerable patients with type 2 diabetes mellitus, established cardiovascular disease, and chronic kidney disease.
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
TLDR
Patients with type 2 diabetes at high risk for cardiovascular events who received empagliflozin, as compared with placebo, had a lower rate of the primary composite cardiovascular outcome and of death from any cause when the study drug was added to standard care.
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
TLDR
Patients treated with canagliflozin had a lower risk of cardiovascular events than those who received placebo but a greater risk of amputation, primarily at the level of the toe or metatarsal.
...
...